The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases
Open accessAbstract
Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2. Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2. We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7-82%) for BRCA1 mutation carriers and 74% (7-94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6-65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2. At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2, the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., & Stratton, M. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 873
BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer
Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., Jablon, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362002 · Cited by 685
Struewing, J. P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M. M., Collins, F. S., & Brody, L. C. (1995) · Nature Genetics · doi:10.1038/ng1095-198 · Cited by 647
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Ford, D., Easton, D. F., & Peto, J. (1995) · Europe PMC (PubMed Central) · Cited by 528
Gayther, S. A., Warren, W., Mazoyer, S., Russell, P. A., Harrington, P. A., Chiano, M., Seal, S., Hamoudi, R., van Rensburg, E. J., Dunning, A. M., et al. (1995) · Nature Genetics · doi:10.1038/ng1295-428 · Cited by 496
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Gayther, S. A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B. A. J., Stratton, M. R., & Easton, D. (1997) · Nature Genetics · doi:10.1038/ng0197-103 · Cited by 442
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., Eijk, R. V., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/513891 · Cited by 387
Population-based study of risk of breast cancer in carriers of BRCA2 mutation
Thorlacius, S., Struewing, J. P., Hartage, P., Olafsdottir, G. H., Sigvaldason, H., Tryggvadottir, L., Wacholder, S., Tulinius, H., & Eyfjörd, J. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03300-5 · Cited by 348
Newman, B. (1998) · JAMA · doi:10.1001/jama.279.12.915 · Cited by 345
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer
Neuhausen, S., Gilewski, T., Norton, L., Tran, T., McGuire, P., Swensen, J., Hampel, H., Borgen, P., Brown, K., Skolnick, M., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-126 · Cited by 304
Study of a single BRCA2 mutation with high carrier frequency in a small population.
Thorlacius, S., Sigurðsson, S., Bjarnadóttir, H., Ólafsdóttir, G. H., Jonasson, J. G., Tryggvadóttír, L., Tulinius, H., & Je, E. (1997) · Europe PMC (PubMed Central) · Cited by 294
BRCA1 Mutations in a Population-Based Sample of Young Women with Breast Cancer
Langston, A. A., Malone, K. E., Thompson, J. D., Daling, J. R., & Ostrander, E. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601183340301 · Cited by 286
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.
Smith, T. M., Lee, M. K., Szabo, C. I., Jerome, N., McEuen, M., Taylor, M., Hood, L., & King, M. C. (1996) · Genome Research · doi:10.1101/gr.6.11.1029 · Cited by 275
Hopper, J. L., Southey, M. C., Dite, G. S., Jolley, D. J., Giles, G. G., McCredie, M. R. E., Easton, D. F., & Venter, D. J. (1999) · PubMed · Cited by 260
BRCA1 MUTATIONS IN WOMEN ATTENDING CLINICS THAT EVALUATE THE RISK OF BREAST CANCER
Ouch, F. E. J. C., Hano, M. I. L. D. E. S., Nne, M. A. A., Athleen, K., Topfer, J. I. S., Ampeau, L. I. C., Ebbeck, T. I. R., & Eber, A. L. W. (1997) · Cited by 256
Malone, K. E., Daling, J. R., Thompson, J. D., O'Brien, C. A., Francisco, L. V., & Ostrander, E. A. (1998) · JAMA · doi:10.1001/jama.279.12.922 · Cited by 249
Cohort Study Analysis with a FORTRAN Computer Program
COLEMAN, M., DOUGLAS, A., HERMON, C., & PETO, J. (1986) · International Journal of Epidemiology · doi:10.1093/ije/15.1.134 · Cited by 249
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
Jóhannesdóttir, G., Guðmundsson, J., Bergþorsson, J. Þ., Arason, A., Agnarsson, B. A., Eiríksdóttir, G., Johannsson, O. T., Borg, Å., Ingvarsson, S., Easton, D. F., et al. (1996) · PubMed · Cited by 223
Differential Contributions of BRCA1 and BRCA2 to Early-Onset Breast Cancer
Krainer, M., Silva-Arrieta, S., FitzGerald, M. G., Shimada, A., Ishioka, C., Kanamaru, R., MacDonald, D. J., Unsal, H., Finkelstein, D. M., Bowcock, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362003 · Cited by 210
Risk models for familial ovarian and breast cancer
Antoniou, A. C., Gayther, S. A., Stratton, J. F., Ponder, B. A. J., & Easton, D. F. (2000) · Genetic Epidemiology · Cited by 192
Germline BRCA1 185delAG mutations in Jewish women with breast cancer
Offit, K., McGuire, P., Schluger, A. E., Hampel, H., Brown, K., Gilewski, T. A., Norton, L., Swensen, J. J., Neuhausen, S. L., Skolnick, M. H., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91484-1 · Cited by 144
Nordling, M., Karlsson, P., Wahlström, J., Engwall, Y., Wallgren, A., & Martinsson, T. (1998) · PubMed · Cited by 93
Survival in early-onset BRCA1 breast-cancer patients
Ansquer, Y., Gautier, C., Fourquet, A., Asselain, B. J. R., & Stoppa‐Lyonnet, D. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79248-5 · Cited by 80
The Genetics of Inherited Breast Cancer
Gayther, S. A., Pharoah, P. D. P., & Ponder, B. A. J. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018779830743 · Cited by 43
Risk Models for Familial Breast and Ovarian Cancer
Antoniou, A. C., Easton, D. F., Gayther, S. A., Stratton, J. F., & Ponder, B. (1999) · Annals of Human Genetics · doi:10.1046/j.1469-1809.1999.63403511.x · Cited by 8
Cited by
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
The personal and clinical utility of polygenic risk scores
Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0018-x · Cited by 1,623
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086
Metadata
- Venue
- British Journal of Cancer
- Published
- 2000-11
- Volume
- 83
- Issue
- 10
- Pages
- 1301-1308
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W4252946660
- Cited by
- 604
- References
- 34
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.